Validity
Evidence for the Validity of PROMIS® Measures
There is substantial qualitative and quantitative evidence supporting the validity of PROMIS measures. Below are key highlights from the existing body of evidence. To ensure your use of PROMIS is informed by the most current findings, conduct a literature search to identify up-to-date validity evidence specific to your PROMIS domain.
In her seminal book, Psychological Testing, Anne Anastasi wrote, “content validity is built into a test from the outset through the choice of appropriate items.”1 This statement applies to patient-reported outcome measures as well. The content validity of PROMIS measures began at the very start of measure development by interviewing patients and having experts review candidate items (DeWalt et al., 2010). Once candidate items are developed, they undergo empirical testing and many are dropped from the final measure. This could result in loss of content validity. However, a follow-up study, found that PROMIS domain names and definitions remained generally representative of the item banks. Content validity can also be evaluated for specific patient populations after a measure is developed. For example, Forrest and colleagues (2020) evaluated the content validity of pain interference, fatigue, sleep disturbance, and sleep-related impairment measures in children with chronic kidney disease and Crohn’s disease.
1Anastasi A, 1988. Psychological Testing, New York, Macmillan Publishing Company, p. 122-127.
A triplet of articles reported the results of validity evaluations conducted on the first wave of PROMIS data collection. Cella et al., 2010, reported results of initial validation studies of 11 PROMIS item banks measuring components of self-reported physical, mental, and social health, along with a 10-item Global Health Scale. Liu et al., 2010 evaluated the representativeness of the Internet panel that was used for initial calibration of the PROMIS item banks. Rothrock, et al., 2010 compared PROMIS scores across chronic condition variables (e.g., number of comorbidities, whether condition was disabling). Many additional publications since then have expanded the evidence for validity of PROMIS measures.
As a person’s symptoms and function change over time, scores on PROMIS measures are expected to also change. Demonstrating responsiveness to change is done by assessing individuals over time. Often, effect sizes and standardized response means are calculated. There is evidence that PROMIS measures capture change over time in different clinical contexts (e.g., patients starting a new treatment for depression, patients with rheumatoid arthritis initiating a disease-modifying antirheumatic drug, patients with spinal disorders, and children with asthma). Evidence for specific PROMIS measures and patient populations is readily obtainable using a PubMed search.
Validity evidence for PROMIS scores has accumulated in many diseases and clinical conditions. For example, in 2016, a series of articles was published in the Journal of Clinical Epidemiology that evaluated the function of different PROMIS measures across clinical contexts (see overview paper for a summary). The validity evidence presented in this series of papers was unique in that each paper evaluated a single PROMIS domain across multiple conditions in “real-world” clinical settings. Researchers can use the results to judge the appropriateness of a given measure for their target clinical context. They can also use the results as external anchors to support comparative effectiveness research.
Additional evidence for specific PROMIS measures and patient populations is readily obtainable using a PubMed search.
Evidence of validity extends to pediatric, parent proxy, and early childhood parent-report measures.
The NIH-funded Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium conducted multiple validation studies of PROMIS pediatric measures in diverse populations including:
- Children with Crohn’s disease and chronic kidney disease (Forrest et al., 2020)
- Children with cancer (Reeve et al., 2020)
- Children with sickle cell disease (Singh et al., 2019, Singh et al., 2020)
- Children with asthma (Nelson et al., 2021, Nelson et al., 2022)
- Children with type 1 diabetes (Singh et al., 2021)
Making the Case for Using PROMIS
If you are considering a PROMIS measure in a clinic or for a study, you will have substantial evidence to evaluate. The questions you ask about that evidence can also serve as the framework for supporting your choice to others (e.g., administrators, granting agency). Here are some questions you should consider:
- Why is it important to measure this domain or these domains in my study or clinic? Describe the relevance of the symptom or outcome to the population of interest.
- What psychometric evidence has accumulated when this measure was used in my targeted population? If you are not able to find a study in your population, weigh the evidence that exists for the measure across populations.
- It is appropriate to consider evidence gathered about the validity of a measure, even if a different assessment strategy was used (e.g., one short form versus another, CAT versus short form). You should keep in mind that shorter short forms sacrifice some reliability for reduction in response burden.
- What are the alternatives to the PROMIS measures? State clearly why you believe a PROMIS measure is a good choice, particularly for your population and for your particular purpose. Remember, validity resides in the use of the scores.
How to describe psychometric evidence for a grant proposal
Below is an example report of the psychometric properties of a PROMIS instrument within a grant proposal. This is for the PROMIS Sleep Disturbance measures. Remember, however, that the tone, length, and focus are context dependent. Consider the audience when describing the properties of a measure.
Example Grant Text for PROMIS Sleep Disturbance (PROMIS-SD)
The PROMIS-SD items assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of, and satisfaction with, sleep. Sleep Disturbance does not focus on symptoms of specific sleep disorders; those symptoms are addressed in the PROMIS Sleep-Related Impairment bank.
The PROMIS Sleep Disturbance (PROMIS-SD; Buysse et al., 2010) measures have demonstrated strong validity across diverse populations, supporting their use as a robust patient-reported outcome. Their validity has been demonstrated in patients with a wide range of chronic conditions, including Parkinson’s disease (Jones, 2021), lumbar spine disorders requiring decompression (Nie et al., 2023) chronic kidney disease, (van der Willik et al., 2023), atopic dermatitis (Lei et al., 2020), inflammatory bowel diseases like Crohn’s disease (Ananthakrishnan et al., 2013), back pain (Karp et al., 2014), head and neck cancer (Stachler et al., 2014), and in patients receiving renal replacement therapy (Hussain et al., 2022). Validity has also been demonstrated in postmenopausal women (Trigg et al., 2025), parents of infants in neonatal intensive care units (Busse et al., 2013), individuals with neurological conditions (Cook et al., 2012), and patients with pelvic pain (Fenton et al., 2011).
Specifically, known-groups and convergent validity are supported by PROMIS-SD’s ability to distinguish between clinical and non-clinical populations and to correlate as expected with related health outcomes and established sleep measures. PROMIS-SD demonstrates strong discrimination for moderate to severe insomnia, qualitative content overlap with legacy sleep instruments, and sensitivity to change over time. Clinical validity is further supported in both interventional and observational studies, where PROMIS-SD is responsive to differences in sleep-related health status among adults reporting disturbed versus non-disturbed sleep. In addition, PROMIS-SD scores, particularly when considered alongside negative effects, have been shown to predict global ratings of improvement and the return of active disease. Collectively, this extensive validation across multiple clinical conditions, age groups, and administration formats supports PROMIS-SD as a reliable and versatile tool for assessing sleep disturbance in both clinical and research settings.
International Classification of Functioning, Disability, and Health
The World Health Organization’s (WHO) International Classification of Functioning, Disability, and Health (ICF) is a classification system for health and function. Communication is improved by organizing information and using shared terminology.
In 2014, Tucker and colleagues compared PROMIS and ICF conceptual frameworks and found similarities (see Tucker, Cieza et al., 2014). They then mapped 1,006 PROMIS adult items to the ICF (see Tucker, Excorpizo et al., 2014). In 2025, Langer and colleagues mapped the PROMIS v2.0 Physical Function item bank to the ICF. They found the PROMIS item bank “reveals broad ICF concept coverage…primarily of Mobility and Self-care” (see Langer et al., 2025).
Researchers familiar with the ICF can review these two publications to identify PROMIS measures and items aligned with ICF concepts.
Last updated: October 22, 2026